Engineering a dual vaccine against COVID-19 and tuberculosis
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1273019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Carlyn Monèt Guthrie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK, United States. Hauptthemen laut MEDLINE: COVID-19, Tuberculosis, Communicable Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The COVID-19 pandemic, caused by SARS-CoV-2 virus, has been one of the top public health threats across the world over the past three years. Mycobacterium bovis BCG is currently the only licensed vaccine for tuberculosis, one of the deadliest infectious diseases in the world, that is caused by Mycobacterium tuberculosis . In the past decades, recombinant M.bovis BCG has been studied as a novel vaccine vector for other infectious diseases in humans besides tuberculosis, such as viral infections. In the current study, we generated a recombinant M. bovis BCG strain AspikeRBD that expresses a fusion protein consisting of M. tb Ag85A protein and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein using synthetic biology technique. Our results show that the recombinant M. bovis BCG strain successfully expressed this fusion protein. Interestingly, the recombinant M. bovis BCG strain AspikeRBD significantly induced SARS-CoV-2 spike-specific T cell activation and IgG production in mice when compared to the parental M.bovis BCG strain, and was more potent than the recombinant M.bovis BCG strain expressing SARS-CoV-2 spike RBD alone. As expected, the recombinant M. bovis BCG strain AspikeRBD activated an increased number of M. tb Ag85A-specific IFNγ-releasing T cells and enhanced IgG production in mice when compared to the parental M.bovis BCG strain or the BCG strain expressing SARS-CoV-2 spike RBD alone. Taken together, our results indicate a potential application of the recombinant M. bovis BCG strain AspikeRBD as a novel dual vaccine against SARS-CoV-2 and M. tb in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK, United States.
- Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, OK, United States.
- Department of Physiological Sciences, Oklahoma State University, Stillwater, OK, United States.
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Guthrie, C. M., Tan, X., Meeker, A. C., Self, A. E., Liu, L., & Cheng, Y. (2023). Engineering a dual vaccine against COVID-19 and tuberculosis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1273019
Vancouver
Guthrie CM, Tan X, Meeker AC, Self AE, Liu L, Cheng Y. Engineering a dual vaccine against COVID-19 and tuberculosis. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1273019
BibTeX
@article{Guthrie2023,
author = {Guthrie, Carlyn Monèt and Tan, Xuejuan and Meeker, Amber Cherry and Self, Ashton Elisabeth and Liu, Lin and Cheng, Yong},
title = {Engineering a dual vaccine against COVID-19 and tuberculosis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1273019}
}
EUVIMED